CRNX — Crinetics Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $9.00bn
- $7.80bn
- $7.70m
U.S. STOCKS ON THE MOVE-Synchrony Financial, Coinbase, Versant Media Group
U.S. STOCKS ON THE MOVE-Qualcomm, Costco, Topgolf Callaway Brands
Crinetics climbs after reporting over $5 mln in Q4 net product revenue from recently launched drug
Crinetics Pharmaceuticals reports prelim Q4 revenue
Brief: Crinetics Announces First Patient Dosed In Phase 1/2 Trial Evaluating Crn09682
Brief: Crinetics Announces First Patient Randomized In Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine In Carcinoid Syndrome
Brief: Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals Q3 revenue misses estimates
Brief: Crinetics Pharmaceuticals Q3 Net Income USD -130.091 Million
U.S. RESEARCH ROUNDUP-Carmax, Mirion Technologies, Valmont Industries
Crinetics Pharmaceuticals jumps on US FDA approval of oral pill for rare hormone disorder
U.S. RESEARCH ROUNDUP- Carmax, Mirion Technologies, Valmont Industries
US FDA approves Crinetics' oral pill for rare hormone disorder (updated)
Brief: Crinetics Announces FDA Approval Of Palsonify (Paltusotine) For The Treatment Of Adults With Acromegaly
Brief: Crinetics Pharmaceuticals Announces FDA Approval Of Palsonifytm (Paltusotine) For Treatment Of Adults With Acromegaly
US FDA approves Crinetics' oral pill for rare hormone disorder
U.S. RESEARCH ROUNDUP- Autozone, Pfizer, Valley National Bancorp
Crinetics Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Crinetics Pharmaceuticals Q2 Net Income USD -115.637 Million